Publication: Transcriptomics-based drug repurposing unravels novel therapeutic strategies in AML
No Thumbnail Available
Date
2022-11-16
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Acute myeloid leukemia (AML) is a disease of the hematopoietic system in which abnormal cells
multiply rapidly, accumulate in the blood and bone marrow, and prevent the production of healthy
blood cells. To date, first-line treatment of AML has been based primarily on conventional
chemotherapy. Despite progress, the rate of complete remission in AML remains low, especially in
older patients, and the relapse rate after complete remission remains high. The combination of clinical
and laboratory data has been shown to play an important role in the development of new therapeutic
strategies in AML, in addition to features of tumor histopathogenesis and transcriptional regulation.
1
Therefore, we integrated transcriptomics data from relapsed, refractory, and previously untreated
AML patients based on their response to therapy using disease-specific signatures with biological and
pharmacological data to enable rational identification of the potential of signaling pathways and drugs
in AML. Based on the integration of transcriptomics data, we identified eight drug candidates by
repurposing and evaluated their potential by in vitro testing in the HL60 and KG -1 cell lines. Six
repurposed drugs, including nortriptyline, desipramine, doxepin, estramustine, risedronate, and
hydrochlorothiazide, were proposed as potential drug candidates for the treatment of AML. We
confirmed possible mechanisms of action of the drugs on cell viability HL -60 and KG -1 by apoptosis
assays and Western blotting. Given the beneficial effects of the drugs on the apoptosis pathway, our
results are intriguing and suggest that these therapies may prove useful and be potential candidates
for the future treatment of AML.
Description
Keywords
Citation
KELEŞOĞLU N., Korkmaz N. S., TURANLI B., ARĞA K. Y., YILMAZ B., ATEŞ DURU Ö., \"Transcriptomics-Based Drug Repurposing Unravels Novel Therapeutic Strategies in AML\", 4th EURASIA BIOCHEMICAL APPROACHES & TECHNOLOGIES (EBAT) CONGRESS, Antalya, Türkiye, 3 - 06 Kasım 2022